Please login to the form below

Not currently logged in
Email:
Password:

Kythera

This page shows the latest Kythera news and features for those working in and with pharma, biotech and healthcare.

Allergan adds Zeltiq to M&A roster in $2.48n deal

Allergan adds Zeltiq to M&A roster in $2.48n deal

Other deals in the aesthetics sector include Allergan's $2.1bn purchase of Kythera in 2015, bringing in double chin-reducing therapy Kybella (deoxycholic acid), and the takeover of regenerative medicine

Latest news

  • Allergan buys regenerative medicine firm LifeCell for $2.9bn Allergan buys regenerative medicine firm LifeCell for $2.9bn

    Those are headed by blockbuster wrinkle treatment Botox but also include Kybella - bought along with Kythera last year for $2.1bn - for reducing double chins and dermal filler Juvederm.

  • Rare disease therapies head the ‘class of 2015’ Rare disease therapies head the ‘class of 2015’

    Kythera Biopharma created a new therapeutic category in the pharma/cosmetic area with Kybella (deoxycholic acid), the first drug for reducing double chin, while Sprout Pharma chalked up the first approval ... Kybella. submental contouring (double chin).

  • Allergan inks $2.1bn deal to buy cosmetic drug firm Kythera Allergan inks $2.1bn deal to buy cosmetic drug firm Kythera

    Allergan inks $2.1bn deal to buy cosmetic drug firm Kythera. Company will add Kythera’ s double chin therapy Kybella to its portfolio. ... The M&A juggernaut in the specialty pharma sector shows no signs of slowing down with Allergan paying $2.1bn to

  • Kythera bags FDA approval for double chin therapy Kythera bags FDA approval for double chin therapy

    Kythera bags FDA approval for double chin therapy. Comes as cosmetics industry sees major growth. ... Kythera has also filed for approval of Kybella in Canada, Switzerland and Australia and has indicated it intends to submit it in Europe this year.

  • Biologics buoyant

    Intendis has taken rights to Kythera Biopharmaceuticals' phase II stage product, ATX-101, outside the US and Canada in a deal worth $373m, including an upfront payment of $43m. ... The licence with Intendis includes all potential indications for ATX-101

More from news
Approximately 3 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Pharma deals in June 2015 Pharma deals in June 2015

    Pharma deals in June 2015. Allergan's $2.1bn acquisition of Kythera tops this month's deals. ... Kythera Biopharmaceuticals/ Allergan. Rx aesthetic medicine products - incl Kybella for double chin (FDA approved).

  • Pharma deals during March 2014 Pharma deals during March 2014

    This seems to have been the case with Kythera Biopharmaceuticals and its partner since 2010, Bayer Healthcare's Consumer Care Division. ... Citing a change in strategic focus, Bayer is selling back the rights to ATX-101 to Kythera.

  • Deal Watch table for March 2014 Deal Watch table for March 2014

    102. Bayer/ Kythera Biopharmaceuticals. Buy back of rights ex US, Canada (Aug 2010 deal).

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

  • Hospira CEO joins board of Kythera Hospira CEO joins board of Kythera

    Hospira CEO joins board of Kythera. Michael Ball named director of aesthetic medicine specialist. ... Kythera Biopharmacueticals has appointed Hospira's CEO Michael Ball to the company's board of directors.

More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
EY Life Sciences

Our global reach Against a backdrop of regulatory, digital, financial and global transformation, Life Sciences companies are finding integration and...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics